Article thumbnail

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia

By Lada Beara-Lasic, Michael H Pillinger and David S Goldfarb


Gout recently passed rheumatoid arthritis to become the most common inflammatory arthritis in the United States (US). However, epidemiologic studies indicate that the quality of gout management is suboptimal owing to both patient and physician issues. Only three options for urate-lowering therapy are currently available in the US: allopurinol, probenecid, and recently, febuxostat. Probenecid is generally safe except for the occurrence of urolithiasis, but is only effective for the subset of patients with better kidney function. Allopurinol use is limited due to its side effects, potential toxicity of uncertain magnitude in patients with renal disease, and failure to achieve targeted serum urate levels. In part this failure may be due to the necessity for it to be titrated for optimal therapeutic effect. Febuxostat is a new medication that may offer several advantages and can be given as an alternative to allopurinol. We review the basic biology and clinical performance of febuxostat, and consider the potential utility of this agent in comparison to the older, better-established gout therapeutics

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. 24-h uric acid excretion and the risk of kidney stones.
  2. (2009). A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep.
  3. (2005). a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum.
  4. (2007). A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther.
  5. (2007). Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial.
  6. (1993). Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother.
  7. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.
  8. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
  9. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
  10. (2008). Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, doubleblind, parallel-group trial. Arthritis Rheum.
  11. (2008). Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum.
  12. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis.
  13. (1994). Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant.
  14. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
  15. (2009). Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology
  16. (2006). Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother.
  17. for chronic treatment of gout.
  18. (2008). Gout and coronary artery disease: epidemiologic clues. Curr Rheumatol Rep.
  19. Gout and hyperuriciemia.
  20. (2008). Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis.
  21. (2009). Gout management in primary care vs rheumatology: evidence for suboptimal treatment. Arthritis Rheum.
  22. (2009). Gout Study Group: update on hyperuricemia and gout. Joint Bone Spine.
  23. Gout-associated uric acid crystals activate the NALP3 inflammasome.
  24. (2007). Hyperuricemia and gout: new insights into pathogenesis and treatment. Bull NYU Hosp Jt Dis.
  25. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees.
  26. (1993). Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents.
  27. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition.
  28. Low urine pH: a novel feature of the metabolic syndrome.
  29. (2004). Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens.
  30. (2006). pharmacodynamics and safety of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet.
  31. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.
  32. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids.
  33. Prevalence of co-morbidities and relative contraindications to standard therapies in a cohort of gout patients.
  34. (2007). Quality of care for gout in the US needs improvement. Arthritis Rheum.
  35. Randomized trial of allopurinol in the prevention of calcium oxalate calculi.
  36. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
  37. (2008). Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study. Arthritis Rheum.
  38. Role of uric acid in hypertension, renal disease, and metabolic syndrome.
  39. (2005). Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci.
  40. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
  41. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
  42. (2009). The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, singleblind pilot study. Ann Rheum Dis.
  43. Urate and calcium stones–picking up a drop of mercury with one’s fingers?